Background-Maternal and inherited (ie, case) genetic factors likely contribute to the pathogenesis of congenital heart defects, but it is unclear whether individual common variants confer a large risk. Methods and Results-To evaluate the relationship between individual common maternal/inherited genotypes and risk for heart defects, we conducted genome-wide association studies in 5 cohorts. Three cohorts were recruited at the Children's Hospital of Philadelphia: 670 conotruncal heart defect (CTD) case-parent trios, 317 left ventricular obstructive tract defect (LVOTD) case-parent trios, and 406 CTD cases (n=406) and 2976 pediatric controls. Two cohorts were recruited through the Pediatric Cardiac Genomics Consortium: 355 CTD trios and 192 LVOTD trios. We also conducted metaanalyses using the genome-wide association study results from the CTD cohorts, the LVOTD cohorts, and from the combined CTD and LVOTD cohorts. In the individual genome-wide association studies, several genome-wide significant associations (P≤5×10 −8
C ongenital heart defects (CHDs) are the most common birth defect, with a prevalence of ≈1 in 100 live births, 1 and account for ≈40% of infant deaths in North America. 2 Although few specific risk factors have been identified for CHDs, a genetic contribution to risk is expected based on narrow sense heritability estimates (h 2 =0.8) [3] [4] [5] and the occurrence of CHDs as part of specific genetic syndromes (eg, 22q11 deletion syndrome). 6, 7 Moreover, familial recurrence patterns indicate that the genetic contribution to nonsyndromic CHDs is likely to be complex and involve multiple, inherited variants of low to moderate effect. 8, 9 Both maternal and inherited (ie, case) genetic factors (and nongenetic factors) are thought to contribute to the risk of CHDs. [10] [11] [12] In addition, different groups of heart defects (eg, conotruncal defects [CTDs] , left ventricular obstructive tract defects [LVOTDs]) may share some genetic risk factors while also having group and even lesion-specific genetic pathogeneses. 10, 13, 14 
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Although much remains to be learned about the genetic contribution to CHDs, genomic approaches, including genome-wide association studies (GWAS), have identified novel candidate genes and loci with relatively strong effects. For example, genome-wide significant and suggestive associations have been reported for CTDs, 15 tetralogy of Fallot, 16 LVOTDs, 17 and septal defects. [18] [19] [20] Most of the reported associations have yet to be independently replicated. Hence, while GWAS have provided some evidence that the risk of CHDs is influenced by common genetic variants, further studies are warranted. Although the majority of GWAS of adult-onset traits have identified weak to moderate effects, stronger effects have been reported for birth defects and other earlyonset traits. 21 Thus, we hypothesized that common individual variants contribute to the genetic architecture of CHD risk.
To agnostically identify a subset of common candidate single-nucleotide polymorphisms (SNPs) for future study, we conducted GWAS in multiple CHD cohorts, as well as metaanalyses of the combined data. Our analyses evaluated associations of CHD with both the maternal and inherited (case) genotypes.
Methods

Study Subjects
Children's Hospital of Philadelphia: CTD Trios CTD case-parent trios were recruited from The Cardiac Center at The Children's Hospital of Philadelphia (CHOP) from 1992 to 2010. 15 Individuals of all races/ethnicities were eligible to participate. All subjects provided informed consent under a protocol approved by the CHOP Institutional Review Board for the Protection of Human Subjects. The CTD diagnoses included tetralogy of Fallot, D-transposition of the great arteries, ventricular septal defects (conoventricular, posterior malalignment, and conoseptal hypoplasia), double outlet right ventricle, isolated aortic arch anomalies, truncus arteriosus, and interrupted aortic arch. Cardiac medical records were reviewed (eg, echocardiography, cardiac magnetic resonance imaging, cardiac catheterization, and operative notes) to ensure accuracy of the cardiac phenotype, and cases with suspected genetic syndromes were excluded. Furthermore, cases were screened for 22q11.2 deletion syndrome using fluorescence in situ hybridization and multiplex ligation-dependent probe amplification.
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Children's Hospital of Philadelphia: LVOTD Trios LVOTD case-parent trios were recruited from the CHOP Cardiac Center, 1997 to 2007, using the same approach as described for the CTD trios. 17 Individuals of all races/ethnicities were eligible to participate. The LVOTD diagnoses included hypoplastic left heart syndrome, coarctation of the aorta with or without bicuspid aortic valve, and aortic valve stenosis. We excluded those with variants of hypoplastic left heart syndrome, such as malaligned atrioventricular canal defects and double outlet right ventricle with mitral valve atresia. Cardiac medical records were reviewed to ensure accuracy of the cardiac phenotype. Cases with suspected genetic syndromes were excluded.
Children's Hospital of Philadelphia: CTD Cases and Pediatric Controls
Additional cases with CTDs were recruited through the CHOP Cardiac Center, 1999 to 2010, using the same approach as described for CTD trios. Controls were also recruited from CHOP, during well child visits, as previously described. 23 Cases and controls were white by self-report.
Pediatric Cardiac Genomics Consortium
CTD and LVOTD case-parent trios were recruited as part of the Pediatric Cardiac Genomics Consortium's (PCGC) Congenital Heart Disease GEnetic NEtwork Study. The recruitment of these subjects has been described. 24 Briefly, subjects provided informed consent and were recruited into the PCGC cohort at 10 clinical study sites from 2010 to 2012. Individuals of all races/ethnicities were eligible to participate. Cardiac diagnoses were classified based on medical record abstraction by trained study coordinators. Although the PCGC cohort included a broad range of CHDs, our analyses were restricted to those with CTDs or LVOTDs.
Genetic Methods
Study subjects in all cohorts provided either blood or saliva samples, and DNA was extracted directly from these samples (or from cell lines in a minority of subjects) using standard methods, as described previously. 6, 20, 24 All samples were array genotyped using Illumina arrays ( Figure 1 ) in the CHOP Center for Applied Genomics.
The array genotype data from the CHOP CTD and LVOTD trios have previously been used to impute additional genotypes against Hapmap reference data, 25 and these genotyped and imputed data were used in our previous GWAS. 15, 17 For the analyses presented here, data for all cohorts were imputed (or reimputed) using data from the 1000 Genomes Project reference data. 26 Given differences in the timing of the availability of data from CHOP and PCGC, data from these 2 sources were imputed separately. However, data from all of the CHOP cohorts were imputed together. Likewise, data from PCGC CTD and LVOTD trios were imputed together. Both sets of imputations (ie, CHOP and PCGC) were based on the genotype data for SNPs that overlapped across all genotyping platforms (ie, SNPs in common to the 550K, 610K, and 2.5M arrays for the CHOP imputation and the 1M and 2.5M arrays for the PCGC imputation). The overlapping set of SNPs was used to minimize differences in imputation accuracy across the cohorts that could arise if imputations were based on different SNPs for each cohort. The imputation and all subsequent analyses were restricted to autosomal variants.
Before imputation, we used PLINK v1.06 27 to perform standard quality control procedures on each study cohort (eg, CHOP CTD trios). We excluded trios with Mendelian error rate >1%; SNPs with minor allele frequency <1%, genotyping rate <90%, or deviation from Hardy-Weinberg equilibrium in controls/parents (P≤1×10 −5 ); and suspected duplicate samples based on pairwise identity by descent pi-hat >0.6. After these exclusions, data from the 3 CHOP cohorts were combined, haplotypes were pre-phased using SHAPEIT2 v2.727 28 and genotypes for additional variants were imputed using Impute 2 v2.3.0, 29 and pre-phased data from the 1000 Genomes Project (Phase-I integrated v3 variants set). 26, 30 Post-imputation quality control procedures included removing variants that were indels, poorly imputed (r 2 <0.8), did not have rs numbers, or rare (minor allele frequency <5%). Variants and individuals with a genotyping rate <90% were also removed. Data from the PCGC CTD and LVOTD trios were combined and processed using the same procedures.
Statistical Analysis
Analytic Groups
We conducted separate GWAS for the 5 independent cohorts: CHOP CTD trios, CHOP LVOTD trios, CHOP CTD cases-controls, PCGC CTD trios, and PCGC LVOT trios ( Figure 1 ). We assessed the inherited (case) genotype in all cohorts and the maternal genotype in the trios.
Family-Based Analyses
The analyses of case-parent trios were conducted using a multinomial likelihood approach 31 implemented in the EMIM software package. 32 Because the assessment of inherited genotypes using this approach is immune to population stratification bias, 33, 34 all trios were included in the analyses of inherited genotypes. However, the assessment of maternal genotypes using trio data can be biased by differences in the frequency of mating types as defined by maternal and paternal race/ethnicity (eg, matings of non-Hispanic white males and Hispanic females are more frequent than the reciprocal mating type). 35 Consequently, analyses of maternal genotypes were restricted to trios in which both parents were reported to be non-Hispanic white.
We used a likelihood ratio test to compare a full model, with terms for both the maternal and inherited genotypes, to a reduced model that excluded the term being tested. We used an additive (1 df) genetic risk model for the genotype being assessed (eg, inherited genotype) and an unrestricted (2 df) model for the other genotype (eg, maternal genotype). Manhattan plots were generated for each comparison using R version 3.03 (http://www.r-project.org/). SNPs with P≤5×10 −8 were considered significantly associated, and SNPs with P values between 10 −5 and 5×10 −8 were considered to have suggestive evidence of association with CTDs and LVOTDs.
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Case-Control Analysis
Using data from the CHOP CTD cases and controls, the association between CTDs and the inherited genotype was assessed using logistic regression, based on an additive genetic risk model. These analyses were adjusted for the first 2 principal components of race/ethnicity and were conducted using Golden Helix v8.1 (Golden Helix, Inc., Bozeman, MT; www.goldenhelix.com), which implements principal component adjustment. The results from this analysis were visualized and interpreted using the same approach described for the familybased analyses.
Replication
For each SNP with at least a suggestive association with CHDs in ≥1 cohort, we examined the P values and effect size estimate from the additional, comparable cohorts. For example, if there was suggestive evidence for an association with the inherited genotype for an SNP in the CHOP CTD case-control cohort, we examined the P values and effect size estimates for that SNP in the analyses of the CHOP and PCGC CTD trios. We deemed associations to be replicated if an SNP had at least suggestive evidence of association (P≤10 −5 ) in >1 data set assessing the same genetic effect (maternal or inherited) and phenotype and consistent direction of association in ≥2 comparable cohorts.
Meta-Analysis
Because there is evidence that subgroups of CHDs (eg, CTDs and LVOTDs) are likely to have overlapping but not identical genetic profiles, we conducted 3 separate meta-analyses of inherited effects, based on the following groupings ( Figure 1 ): CTDs only (CHOP CTD trio, CHOP CTD case-control, and PCGC CTD analyses), LVOTD only (CHOP and PCGC LVOTD trios), and CTD+LVOTD (all 5 cohorts). Likewise, we conducted 3 separate meta-analyses of maternal effects: CTDs only (CHOP and PCGC CTD trios), LVOTD only (CHOP and PCGC LVOTD trios), and CTD+LVOTD (all 4 trio cohorts). Each meta-analysis was performed using a fixed-effects model, unless there was evidence of heterogeneity (based on Cochran heterogeneity P≤0. 1) , in which case a random effects model was used. We conducted meta-analyses using GWAMA v2.1 (http:// www.well.ox.ac.uk/gwama/). 37 Manhattan plots were generated using R version 3.03 (http://www.r-project.org/) and regional association plots were constructed for top hits using Locus Zoom v1.1 (http:// locuszoom.sph.umich.edu/locuszoom/). 38 Variants were annotated with Combined Annotation-Dependent Depletion (CADD) scores. 39 CADD scores predict the potential deleteriousness of individual variants, such that variants with CADD>10 are predicted to fall in the top 10% of the most deleterious variants in the genome. Variants were also annotated with Genome Wide Annotation of VAriants (GWAVA) scores, which are scores for variants and corresponding regions that focus on predicting the functional impact of noncoding variants/regions https://www.sanger.ac.uk/sanger/StatGen_Gwava).
40
Results
After quality control exclusions were applied, there were 670 CHOP CTD trios, 317 CHOP LVOTD trios, 406 CHOP CTD cases/2976 pediatric controls, 355 PCGC CTD trios, and 192 PCGC LVOTD trios. The cohorts were characterized using counts and frequencies for race/ethnicity, sex, and heart defect lesion (Table 1 ). The most frequent CTD was tetralogy of Fallot (30%-40%), and the most common LVOTD was hypoplastic left heart syndrome (44%-50%). Consistent with known epidemiological characteristics of LVOTDs and certain CTDs, 41 there was an excess of males. After quality control exclusions, data were available for 4 756 722 SNPs (n=4 483 243 imputed) in the CHOP cohorts and for 5 737 343 SNPs (n=5 112 962 imputed) in the PCGC cohorts.
GWAS of Individual Cohorts
A GWAS was conducted separately for each cohort (Figure 1) . The total numbers of genome-wide significant and suggestive associations with SNPs observed in each cohort are summarized in Table 2 . Genome-wide significant associations were only identified in the CHOP CTD case-control GWAS. In this analysis, 52 inherited genotypes were significantly associated with CTDs ( ) with the inherited Figure 1 . Schematic of the 5 independent cohorts and summary of which cohorts were analyzed in each meta-analysis. CHD indicates congenital heart defect; CHOP, The Children's Hospital of Philadelphia; CTD, conotruncal heart defect; LVOTD, left ventricular obstructive tract defect; and PCGC, the Pediatric Cardiac Genomics Consortium.
and maternal genotypes were detected in the analysis of each cohort (Table 2 ). However, there was no overlap in the SNPs with at least suggestive evidence of association across comparable cohorts (data not shown). Thus, there was no evidence of replication for any of the suggestive or significant associations identified in the individual cohorts.
Meta-Analyses
There was suggestive evidence of associations with the maternal genotype for multiple SNPs in the meta-analysis of CTD ). However, no genome-wide significant associations with the maternal genotype were identified ( Figure I in the Data Supplement). Furthermore, the maternal genotypes for SNPs in linkage disequilibrium with rs55788414, the SNP with the smallest association P value, were not associated with LVOTD (Figure 2) .
Meta-analyses of the inherited genotype for CTDs only and CTDs+LVOTDs also did not identify any genomewide significant associations ( Figures I and II ; Figure 2 ). The LVOTD meta-analysis also identified 24 additional SNPs, in 14 regions, with suggestive evidence of associations (Table 3 ; Figure I and Table VII in the Data Supplement).
Discussion
Our GWAS of maternal and inherited genotypes and CTDs/ LVOTDs in 5 independent cohorts identified several potential candidate regions. The majority of these signals were present in our case-control analysis, which was likely better powered than our family-based comparisons given the relatively large number of controls. It is noteworthy that nearly all of the genome-wide significant SNPs in the CHOP case-control comparison were intronic variants in MGAT4C, which is involved in the biosynthesis of an N-glycan precursor. There are several congenital disorders of N-linked glycosylation, and there are reports of individuals with these conditions that have a CHD. 42, 43 Two of the SNPs in MGAT4C had CADD scores >10 (rs863392 and rs839163) and are thus predicted to be highly deleterious. However, the GWAVA-TSS (transcription start site) scores for intronic SNPs in MGAT4C were all less than the median value for GWAS SNPs that have been externally replicated. Moreover, as these variants were not significantly related to CTDs in the meta-analysis, it may be that associations identified in our case-control represent falsepositive findings arising from uncontrolled confounding (eg, because of inadequate control for population stratification).
No association met our pairwise replication threshold of P≤10 −5 in >1 data set assessing the same genetic effect (maternal or inherited) and phenotype. However, our meta-analyses identified several genes/regions of interest. We identified 1 inherited SNP (rs72820264, imputed) that was significantly associated with LVOTDs in our meta-analysis. This SNP is in an intergenic region on chromosome 6p24.3, 416 kb from the nearest upstream gene (MRDS1/OFCC1) and 638 kb from the nearest downstream gene (HULC). There were several additional SNPs in the region in strong linkage disequilibrium with rs72820264 that also had low P values (Figure 2 ), including typed variants (eg, rs7762096, P=6.2×10
). There is a strong signal from an ENCODE clustered DNase I hypersensitivity site over 24 tissues, located at chr6:9293081-9293290, ≈1.5 kb away from this SNP (chr6:9291650). A DNAse I hypersensitivity site may indicate a promoter location within this primate-conserved region because regulatory regions, especially promoters, tend to be DNase sensitive. 44, 45 However, GWAVA scores do not support a functional role for this SNP (0.2) or region (0.3). Also, the scaled CADD score was 1.5 for rs72820264, which suggests that this variant is not highly deleterious. The nearest downstream gene, OFCC1 (Orofacial Cleft 1), has been associated with orofacial clefts in several studies. [46] [47] [48] Furthermore, this region (6p24.3-21.2) has been linked to a rare autosomal dominant syndrome that includes heart anomalies (noncompaction of the ventricular myocardium, bradycardia, pulmonary valve stenosis, secundum atrial septal defect, left isomerism, and heterotaxy). 49 Thus, in silico data neither negate nor define the potential contribution of this statistically associated SNP to disease risk.
The top suggestive associations from our meta-analyses included inherited variants in LRP1B (LDL receptor protein) and MGAT4A (regulates Golgi apparatus formation), as well as maternal variants in SLC38A3 (glutamine transporter), HIVEP3 (HIV enhancer-binding protein), and PKD1L2 (polycystin protein involved in transmembrane domains). Of these, the intronic variant in SLC38A3 was predicted to be within the most 10% of deleterious variants in the genome (scaled CADD score: 14.85) and had a GWAVA-TSS score that was within the third quartile of scores for GWAS SNPs that have been externally replicated. This gene is thought to play an important role in fetal development because it likely is the main supplier of glutamine (necessary for fetal growth) to the fetus in early gestation. 50 The maternal intronic variant in PKD1L2 had a borderline significant association with LVOTDs (P=5.5×10 −8 ) but is not predicted to be deleterious based on CADD or GWAVA-TSS scores. However, no SNP in linkage disequilibrium with this PKD1L2 SNP was also associated.
The maternal SNP with the smallest association P value, rs55788414, likely reflects a false-positive finding, given that the maternal genotype for SNPs in linkage disequilibrium with the SNP with were not associated with LVOTD ( Figure 2) .
We had results for 16 SNPs that were previously identified in CHD GWAS, but none were significantly associated with the corresponding phenotype/effect in our meta-analysis (Table VIII in the Data Supplement ). However, some of the phenotypes included in previous GWAS did not directly correspond to those in our cohorts (eg, tetralogy of Fallot versus CTDs; septal defects versus CTDs+LVOTDs). For other traits (eg, adult-onset conditions), it has not been uncommon for GWAS findings to fail to replicate in subsequent GWAS. 51 Potential reasons for lack of replication across GWAS studies include population differences (eg, 3 of the previous CHD GWAS were conducted among Chinese or European samples), genotyping platform/imputation differences, modeling differences, geneenvironment or gene-gene interactions, and differences in case phenotypes (eg, CTDs versus tetralogy of Fallot).
Our results should be considered in light of several limitations. We conducted 9 GWAS analyses and 6 metaanalyses using the typical GWAS threshold for significance of P<5×10 −8 in each analysis. Given that we conducted multiple analyses, this threshold may have been too lenient. In addition, some of our cohorts were small, which limited our ability to detect SNPs that are only modestly associated with CHDs. In addition, our study subjects were recruited from a clinical rather than a population-based setting and, thus, may not be representative of the general population of individuals affected by CHDs. Despite these limitations, our study also had several strengths including a relatively large sample size, as compared with other GWAS of CHDs, and the evaluation of both inherited and maternal genetic effects.
In summary, we report several potential candidate regions for some of the most common, severe heart defects. Our studies suggest that few, if any, single SNPs confer large risk of nonsyndomic CTDs and LVOTDs. More work is needed to address the contribution of common SNPs that confer weak or moderate risk. For example, results from recent GWAS suggest that gene-or pathway-based studies may be required to ). ‡Odds ratio estimate for carrying 1 copy of the high-risk allele compared with no copies, and corresponding 95% CI. §Scaled CADD score (variants with CADD>10 are predicted to fall in the top 10% of the most deleterious variants in the genome). ‖GWAVA score for predicting the functional impact of noncoding variants/regions (range 0-1). ¶GWAS significant (P≤5×10 −8 ).
identify genes that influence risk of CHDs via common variants. 52 Future work might therefore focus on the candidate loci highlighted by these meta-analyses and on gene sets defined by functional or developmental pathways. Otherwise, substantially larger sample sets will be required to identify individual common variants that confer a small to moderate risk for CHDs and to identify risks specific to cardiac subtypes.
